Critical Care Medicine Doctors in Cambridge, MA Accepting Medicare

3 Critical Care Medicine doctors found. Showing 1 - 3

Dr. Samer Abujaber, MB BCH BAO Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 330 Mount Auburn St, Cambridge, MA 02138 Phone: 617-492-3500

Dr. Farbod Nicholas Rahaghi, M.D., PH.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 73 Martin St, Apt 46, Cambridge, MA 02138 Phone: 858-761-5673

William Beckett, MD Internal Medicine - Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 330 Mount Auburn St, Primary Care Center, Cambridge, MA 02138 Phone: 617-499-5055    Fax: 617-499-5045

News Archive

Researchers update extensive toxicology database to track information about drugs toxic effects

Sometimes the cure can be worse than the disease. Pharmaceutical drugs are known for their potential side effects, and an important aspect of personalized medicine is to tailor therapies to individuals to reduce the chances of adverse events.

IPS examines first USAID progress report, released last week

"The United States' main foreign assistance agency is getting widespread plaudits for new data on a series of internal reforms aimed at aid improvement, but some development experts are pointing to a persistent opaqueness from the agency," Inter Press Service reports.

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Biogen Idec and Elan Corporation, plc today announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion for inclusion of an additional risk factor, anti-JC virus (JCV) antibody status, to the product label for TYSABRI in the European Union.

Warburg Pincus affiliates to acquire ReSearch Pharmaceutical Services for $6.10 per share

ReSearch Pharmaceutical Services, Inc. (RPS) announced today it has entered into an agreement to sell the company to affiliates of Warburg Pincus, LLC, the global private equity firm, in an all cash transaction valued at $6.10 per share. The Board of Directors of RPS unanimously approved the acquisition agreement and recommended that RPS shareholders approve the transaction. It is presently anticipated that closing of the transaction will occur in February 2011.

Engineered cells take control of the cells and microenvironment following transplantation

In work that could jumpstart the promising field of cell therapy, in which cells are transplanted into the body to treat a variety of diseases and tissue defects, researchers at Brigham and Women's Hospital (BWH) have engineered cells that could solve one of the key challenges associated with the procedure: control of the cells and their microenvironment following transplantation.

Read more Medical News

› Verified 8 days ago